Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial
- 184 Downloads
We examined quality of life in spouses of men in the Post-Adjuvant Androgen Deprivation trial after radical prostatectomy.
Men at high risk of prostate cancer recurrence were randomized to receive androgen deprivation therapy or observation. Forty-three couples completed telephone interviews every 6 months for 2 years assessing women’s mood disturbance, mental and physical health, and sexual function and bother as well as men’s symptoms and sociodemographic and marital variables. We used linear mixed modeling to explore relationships between wives’ quality of life and time, treatment group, and men’s symptoms.
Women’s mental health functioning improved over time (p < 0.05). Furthermore, women with husbands in the observation group had worse mood disturbance (p = 0.01) and poorer mental health (p = 0.02) than women with husbands in treatment. Men’s symptoms were associated with worse physical health in wives (p = 0.02). Women also reported worse sexual function at 18 and 24 months compared with baseline (p = 0.02), but ratings of sexual bother were unrelated to time, treatment, and symptoms.
These exploratory results are consistent with research demonstrating that spousal cancer-related distress decreases over time. Treatment group differences suggest that an examination of caregiving in the context of uncertainty is warranted. Also, the physical burden of caregiving may intensify when men have more symptoms. To inform interventions, future studies should clarify how treatment and symptoms influence wives’ distress by examining expectations and communication.
KeywordsProstate cancer Quality of life Partners Symptoms
Patients in the PAAD Trial received free study drug from TAP Pharmaceutical (Lake Forest, IL, USA), AstraZeneca (Wilmington, DE, USA), or Schering Plough (Kenilworth, NJ, USA). First author’s work was supported by an NCI Cancer Prevention and Control Training Program, Center for Health Promotion and Prevention Research, University of Texas-Houston School of Public Health–National Cancer Institute/NIH Grant #2R25CA57712. Second author’s work was supported by an NCI K07 career development award (K07 CA113641). Fourth author’s work was supported by an NIH T32 Training Grant (CA079449) and an American Urological Association Foundation Scholarship.
The authors wish to thank Dr. Jane G. Zapka for her comments on this manuscript.
Conflict of interest
The authors do not have a conflict of interest to report. We have full control of all primary data and agree to allow the journal to review the data if requested.
- 1.American Cancer Society (2009) Cancer facts & figures 2009. American Cancer Society, AtlantaGoogle Scholar
- 2.National Comprehensive Cancer Network (2009) National comprehensive cancer network practice guidelines in oncology: Prostate Cancer V.2.2009. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed June 18, 2009
- 6.Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Troncoso P, Pettaway CA (2007) A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the postoperative adjuvant androgen deprivation trial. BJU Int 100:63–69PubMedCrossRefGoogle Scholar
- 8.Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL (2007) General quality of life two years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 21(6):1147–1154CrossRefGoogle Scholar
- 12.Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ, Holland JC for the Cancer and Leukemia Group B (CALGB) (2001) The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 12:633–641CrossRefGoogle Scholar
- 13.Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate cancer survivors. New Engl J Med 358:1250–1261PubMedCrossRefGoogle Scholar
- 18.McNair PM, Lorr M, Droppleman LF (1981) POMS manual, 2nd edn. Educational and Industrial Testing Service, San DiegoGoogle Scholar
- 20.Ware JE, Kosinski M (2001) SF-36 physical and mental health summary scales: a manual for users of version 1, 2nd edn. Quality Metric Incorporated, LincolnGoogle Scholar
- 26.Diggle PJ, Heagerty P, Liang K-Y, Zeger SL (2002) Analysis of longitudinal data, 2nd edn. Oxford University Press, OxfordGoogle Scholar
- 32.Hewitt ME, Greenfield S, Stovall E (eds) (2006) From cancer patient to cancer survivor: lost in translation. The National Academies Press, WashingtonGoogle Scholar
- 40.Bodenmann G (1997) Dyadic coping—a systemic-transactional conceptualization of stress and coping among couples: theory and empirical findings. Eur Rev Appl Psychol 47:137–140Google Scholar